Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Sponsor: University of Maryland, Baltimore
Summary
This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposure prophylaxis for HIV prevention and buprenorphine for treatment of opioid use disorder when clinically indicated.
Official title: A Novel Model of Hepatitis C Treatment as Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
198
Start Date
2017-05-01
Completion Date
2026-01
Last Updated
2025-03-18
Healthy Volunteers
No
Conditions
Interventions
Evaluate model of care for HCV-infected adults with on-going opioid misuse
Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
Locations (2)
HIPS
Washington D.C., District of Columbia, United States
University of Maryland Drug Treatment Center
Baltimore, Maryland, United States